Options for the treatment of gemcitabine-resistant advanced pancreatic cancer.

  title={Options for the treatment of gemcitabine-resistant advanced pancreatic cancer.},
  author={Ioannis G Gounaris and Kamarul Ahmad Zaki and Pippa G. Corrie},
  journal={JOP : Journal of the pancreas},
  volume={11 2},
CONTEXT Pancreatic cancer is noteworthy in that the number of patients dying from the disease is roughly equal to the number diagnosed. For more than a decade, gemcitabine has constituted the standard of care for the palliative treatment of the majority of patients who present with metastatic or relapsed disease, although the survival gains are limited. Despite a median survival of less than 6 months, there is a significant proportion of advanced pancreatic cancer patients who progress on… CONTINUE READING


Publications referenced by this paper.
Showing 1-10 of 70 references

A randomised trial in patients with gemcitabine-refractory pancreatic cancer

  • U Pelzer, K Kubica, J Stieler, I Schwaner, G Heil, M Görner
  • Final results of the CONKO 003 study. J Clin…
  • 2008
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…